Role of CD47 in Hematological Malignancies

Table 1 Therapeutics targeting CD47 in hematological malignancies

Drug	Type/target	Target	Phase	Malignancy type	References
B6H12.2	Humanized anti-CD47-IgG4	CD47-SIRP α	Cell lines, animal model	B-cell NHL, PEL, MM	[30] [37, 48]
Hu5F9-G4	Humanized anti-CD47-IgG4	CD47-SIRPα	Phase 1	B-cell NHL AML	[34, 44], NCT02678338
CC-90002	Humanized anti-CD47-IgG4	CD47-SIRPα	Phase 1	B-cell NHL	[51], NCT02367196
C47B157 C47B161 C47B222	Humanized anti-CD47-IgG1	CD47-SIRPα	Animal model	AML	[43, 44]
SRF231	High-affinity anti-CD47 Antibody	CD47-SIRPα	Cell lines, animal model, phase1	B-cell NHL	[52], NCT03512340
ALX148	High-affinity SIRPα-Fc Antibody	CD47-SIRPα	Cell lines, animal models	B-cell NHL	[53]
W6/32	Antibody	CD47-MHC-1	Cell lines, animal models	TCL	[35]
4N1K and 4N1	CD47-SIRPα Peptide agonist	CD47-SIRPα	Cell lines	B-cell NHL	[11, 54]
TTI-621	Human SIRPα-Fc fusion IgG1 Peptide Agonist	CD47-SIRPα	Phase 1	MDS, AML, MM, B-ALL, T-ALL, SS	[36, 55] NCT02663518
TTI-622	Human SIRPα-Fc fusion IgG4 Peptide Agonist	CD47-SIRPα	Phase 1	NHL, MM, c-HL	[56], NCT03530683
PKHB1	CD47 Peptide Agonist	CD47-SIRPα	Cell lines, Animal model	T-ALL	[57, 58]
SEN177	Antibody	QPCTL on CD47	Cell lines	BL	[59]
MiR-708	Mi-RNA	CD47-SIRPα	Cell lines, animal model	T-ALL	[60]
MiR-155	Mi-RNA	CD47-SIRPα	Animal model	MM	[49]
NI1701+ Rituximab	BsAb	CD47, CD19, CD20	Cell lines, animal model	NHL	[61]
Anti-CD47 and PD-L1	BsAb	CD47-PD-L1	Cell lines, animal model	T-LBL/ALL	[62,63,64,65]
Anti-(CD47&CD20)	BsAb	CD47-CD20	Cell lines, animal model	NHL	[66]
LicMABs	BsAb	CD47-CD33	Cell lines, animal model	AML	[67]

ISSN: 1756-8722